POLYCLONAL ANTIBODY MARKET ANALYSIS

Polyclonal antibodies are a heterogeneous mix of antibodies derived from the immune response of multiple B-cells, in which each one recognizes a different epitope on the same antigen. Polyclonal antibodies are composed of a mixture of antibodies that represent the natural immune response to an antigen. Polyclonal antibodies are used in general research applications. Moreover, increasing incidence of cancer across the globe is expected to boost the market growth. According to an article published by Cancer Research UK in 2015, 55,122 new cases of breast cancer were registered in 2015. In the U.K., breast cancer was the most common cancer, accounting for 15% of all new cancer cases in 2015.

The global polyclonal antibody market is estimated to be valued at US$ 943.6 million in 2020 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).

Figure 1. Global Polyclonal Antibody Market Share (%), by Region, 2020

Rising cases of infectious diseases are expected to propel growth of the global polyclonal antibody market.

Rising incidence of infectious diseases such as Ebola virus worldwide, especially in under-developed countries, is expected to drive the market growth during the forecast period. For instance, according to an article published by the World Health Organization (WHO) in February 2020, the outbreak of Ebola virus in West Africa was the largest outbreak during 2014-2016 and it still continues in various countries. The facts and figures are given below:

Table 1. Ebola virus disease outbreak

Figure 2. Global Polyclonal Antibody Market Share (%), by Type, 2020

The ongoing development of polyclonal antibodies in North America is expected to drive the market growth.

North America is expected to hold dominant position in the global polyclonal antibody market owing to ongoing research and development in the region. For instance, in August 2018, SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, announced that its anti-Ebola immunotherapy, SAB-139, offers100% protection against a lethal dose of the Ebola virus in an animal study published in The Journal of Infectious Diseases. The study was conducted by the National Interagency Confederation for Biological Research in collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC).

Global Polyclonal Antibody Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

Lockdowns in various countries have placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products, and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is expected to limit growth of the global polyclonal antibody market during the forecast period.

Key Players

Major players operating in the global polyclonal antibody market are Abcam plc, GenScript, Merck KGaA., IgY Immune Technologies & Life Sciences Inc., Thermo Fisher Scientific Inc., Takara Bio Inc., Genway Biotech, Inc., Geno Technology Inc., DC Biosciences Ltd., Good Biotech Corp, Rockland Immunochemicals, Inc., EpiGentek Group Inc., Innovagen AB., and GeneTex, Inc. among others.